BERLIN--(BUSINESS WIRE)--NOXXON announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF). NOXXON will receive approximately one million Euro in research funding under the BioChancePlus initiative, a program that supports innovative research in biotechnology companies. The program is dedicated to further strengthen and broaden NOXXON’s drug discovery platform to identify innovative medicines based on mirror-image oligonucleotides (Spiegelmers®). NOXXON’s Chief Scientific Officer Dr. Sven Klussmann commented: “We are delighted that the government has decided to reward NOXXON’s excellent research. The funding will be beneficial in supporting the development and growth of existing and new technologies.”
